Andrykowski M A, Cordova M J, Studts J L, Miller T W
Department of Behavioral Science, University of Kentucky College of Medicine, Lexington 40536-0086, USA.
J Consult Clin Psychol. 1998 Jun;66(3):586-90. doi: 10.1037//0022-006x.66.3.586.
The presence of a posttraumatic stress disorder (PTSD) diagnosis in women (n = 82) diagnosed with Stage 0-IIIA breast cancer was assessed 6 to 72 months after cancer therapy. The PTSD Checklist-Civilian Version (PCL-C) and the PTSD module for the Structured Clinical Interview for DSM-IV, Nonpatient Version, PTSD module (SCID-NP-PTSD) were administered in a telephone interview. SCID-NP-PTSD results indicated prevalence rates of 6% and 4% for current and lifetime PTSD, respectively. Use of the recommended cutoff score of 50 on the PCL-C to determine diagnosis of current cancer-related PTSD resulted in a sensitivity of .60 and a specificity of .99 with 2 false-negative diagnoses. In conclusion, PTSD can be precipitated by diagnosis and treatment of breast cancer, and the PCL-C can be a cost-effective screening tool for this disorder.
对82名被诊断为0-IIIA期乳腺癌的女性在癌症治疗后6至72个月进行创伤后应激障碍(PTSD)诊断情况的评估。通过电话访谈使用创伤后应激障碍检查表-平民版(PCL-C)和用于《精神疾病诊断与统计手册》第四版非患者版结构化临床访谈的创伤后应激障碍模块(SCID-NP-PTSD)。SCID-NP-PTSD结果表明,当前PTSD和终生PTSD的患病率分别为6%和4%。使用PCL-C上推荐的50分临界值来确定当前与癌症相关的PTSD诊断,敏感性为0.60,特异性为0.99,有2例假阴性诊断。总之,乳腺癌的诊断和治疗可引发PTSD,PCL-C可作为该疾病具有成本效益的筛查工具。